Executive Director, Clinical Research - Neurodegeneration

Alnylam Pharmaceuticals is seeking an imaginative physician drug developer. This is an opportunity to provide clinical leadership in developing RNAi therapeutics in Alnylam’s rapidly expanding portfolio, which spans the areas of rare genetic diseases, cardio-metabolic diseases, neuroscience, hematology and hepatology.

The successful candidate’s primary role will be to drive the pipeline forward through leadership of clinical development programs.  While the primary focus responsibility will be as clinical lead physician on Alnylam’s Huntington’s program, the role may support across a range of therapeutic areas and all stages of development may be required as pipeline assets evolve. The Executive Director is expected to play a leading and influencing role in the overall clinical development strategies and drive progress and operational excellence for associated clinical trials. In addition, this role will include interaction with Alnylam’s research group, helping to advise the team on the clinical development feasibility of novel targets and the design of proof-of-concept studies. This work will also involve extensive consultation and collaboration with external experts. It is expected that additional opportunities will arise to lead bench-to-bedside early phase clinical development programs.

The Executive Director, Clinical Research, will work in a matrix organization across Regulatory, Biostatistics, Clinical Operations, Preclinical, Commercial & QA teams to ensure fully harmonized and integrated development strategies. They will be a key Alnylam Development spokesperson at external meetings, including regulatory interactions and scientific meetings.

This position is hybrid, requiring weekly onsite presence and will be primarily located at our Cambridge, MA headquarters or Maidenhead, UK location. Relocation may be possible for the selected candidate.